[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"sleep\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:sleep":25},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,206,0,25,[9,42,74,106,134,157,187,208,247,273,291,319,345,366,391,429,451,471,489,516,535,555,585,609,636],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":12,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":26,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":41},"100636499","stress-coping-and-sleep-health-study-100636499",false,"NCT07566481","Stress, Coping, and Sleep Health Study","* INCLUSION CRITERIA:\n\nIn order to be eligible to participate in a FGD for this study, an individual must meet all of the following criteria:\n\n1. Adult (aged 18 years or older) living in Ohio, US\n2. Self-identify as Bhutanese-Nepali or Bhutanese American\n3. Identify as a refugee\n4. Speak and understand English and\u002For Nepali.\n5. Ability to understand and the willingness to provide informed consent and participate in the FGD\n\nIn order to be eligible to participate in a KII for this study, an individual must meet all of the following criteria:\n\n1. Adult (aged 18 years or older)\n2. Ability to speak and understand English; Familiarity with the lives and experiences of Bhutanese refugees living in Ohio, US\n3. Ability to understand and the willingness to provide informed consent and participate in the virtual KII.\n\nEXCLUSION CRITERIA:\n\nIndividuals who are unable to communicate in either English or Nepali will be excluded from FGD. Since Nepali is the primary language spoken by most Bhutanese refugees before relocation, and English is the dominant language in the United States, participants are expected to have sufficient proficiency in at least one of these languages.\n\nIndividuals who are unable to communicate in English will be excluded from KII. Given their leadership roles and interactions with the healthcare system, educational institutions, local government service providers, and nonprofit organizations in Ohio-where English is the primary language-participants are expected to have sufficient English proficiency. We will not exclude any participants that meet the inclusion criteria from participating in the study overall or in any of the study procedures.\n\nChildren (individuals under 18) are excluded from this study because the knowledge sought is not relevant to this population. This study investigates the relationship between sleep quality and experiences of discrimination among Bhutanese-Nepali refugees in Ohio, as well as the coping mechanisms adults use to manage discrimination-related stress, particularly as it pertains to sleep.\n\nThe constructs under investigation, including perceived discrimination, its psychosocial impact, and adaptive coping strategies, are anchored in the adult experience of resettlement and the stressors associated with adult social and occupational life. Children's experiences of discrimination, sleep patterns, and coping mechanisms differ substantially from those of adults in both nature and context, and findings from an adult sample would not be generalizable to a pediatric population. For these reasons, the inclusion of children would not yield scientifically meaningful data relevant to the study aims.","ALL","18 Years","120 Years",{"count":20,"type":21},70,"ESTIMATED","OBSERVATIONAL","Background:\n\nPoor sleep is common among refugee groups worldwide. It can lead to an increased risk of heart disease, diabetes, cancer, and premature death. It can also worsen mental health disorders. Researchers have studied the mental health issues among refugees from Bhutan in the United States. Now they want to understand more about how difficulty sleeping may relate to their other health outcomes.\n\nObjective:\n\nTo learn how the social and environmental conditions Bhutanese refugees affect their sleep health and health outcomes.\n\nEligibility:\n\nRefugees aged 18 years and older of Bhutanese-Nepali or Bhutanese American descent. The participants must live in central Ohio. Also needed are people aged 18 years and older who interact with Bhutanese refugees in this region.\n\nDesign:\n\nParticipants will participate in a focus group discussion. The group will have 8 to 10 participants. It will last 60 to 90 minutes.\n\nThey will talk about their experiences as a refugee and their sleep health. Topics may include adjusting to a new culture; access to housing and health care; and experiences with differential treatment by members inside and outside of their group. The study team will audio record the discussion. They will not share the recording with anyone.\n\nParticipants will complete a short questionnaire. They will answer questions about their age, sex, language preferences, and how long they have lived in the United States.\n\nParticipants who are not refugees will take part in a virtual interview led by a member of the study team. Participants will share their experiences with adapting to a new culture, differential treatment, and other factors have affected refugees sleep. The interview will take about 1 hour.",[25],"Sleep",[27,25,28],"Refugee","Discrimination","NOT_YET_RECRUITING","2026-08-20",{"date":32,"type":33},"2026-08-21","ACTUAL",{"date":35,"type":21},"2026-08-26",{"date":37,"type":21},"2026-12-31",{"name":39,"class":40},"National Institute of Environmental Health Sciences (NIEHS)","NIH",1,{"id":43,"slug":44,"hasResults":12,"nctId":45,"briefTitle":46,"officialTitle":47,"acronym":4,"eligibilityCriteria":48,"healthyVolunteers":49,"sex":16,"minAge":50,"maxAge":51,"enrollmentInfo":52,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":54,"conditions":55,"keywords":59,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":67,"lastUpdatePostDateStruct":68,"startDateStruct":70,"completionDateStruct":4,"leadSponsor":72,"locationsCount":41},"100192257","studying-childhood-onset-behavioral-psychiatric-and-developmental-disorders-100192257","NCT01778504","Studying Childhood-onset Behavioral, Psychiatric, and Developmental Disorders","Diagnosis of Childhood-onset Behavioral Disorders, Neuropsychiatric Disorders and Neurodevelopmental Disorders","* INCLUSION CRITERIA:\n\nParticipants will be eligible if they:\n\n1. Are 30 days to 99 years old.\n2. Either:\n\n   -Have a diagnosed neuropsychiatric disorder or neurodevelopmental disability or related symptoms without a formal diagnosis\n\n   OR\n\n   -Are a biological relative of someone who meets the criteria above.\n3. Have the ability to understand and sign an informed consent on behalf of themselves, or have a legal guardian (or designated DPA).\n4. Are under the care of a primary physician.\n\nEXCLUSION CRITERIA:\n\nParticipants will not be eligible if they:\n\n1. Are unwilling or unable to be evaluated and followed as clinically indicated. Examples might include children with severe behavioral problems who refuse physical examination.\n2. The participant does not have a primary healthcare provider.",true,"30 Days","99 Years",{"count":53,"type":21},1000,"Background:\n\n\\- Many psychiatric, behavioral, and developmental disorders are genetic. This means that they tend to run in families. Some begin in childhood, while others do not appear until adulthood. Researchers want to look at people of all ages who have these disorders that started in childhood. They will also look at relatives of people with these disorders. This information will allow doctors to learn more about childhood behavioral problems and how they are inherited. It may also help doctors treat those disorders.\n\nObjectives:\n\n\\- To study the onset and treatment of childhood behavioral, psychiatric, and developmental disorders.\n\nEligibility:\n\n* Individuals of any age who have a psychiatric, autism spectrum, or developmental disorder, or other behavioral problems.\n* Family members of individuals with the above disorders. This group may include parents, grandparents, siblings, aunts\u002Funcles, cousins, and children.\n\nDesign:\n\n\\- Participants will be screened with a medical history and physical exam. They may have a psychiatric history with tests of thinking, judgment, and behavior....",[56,57,58,25],"Neuropsychiatric Disorder","Neurological Disorder","Neurodevelopmental Disorder",[60,61,62,63,64,65],"Natural History Study","Mental Illness","Autism","Developmental Delay","Genetic Disorder","Natural History","RECRUITING","2026-08-14",{"date":69,"type":33},"2026-08-17",{"date":71,"type":33},"2012-12-27",{"name":73,"class":40},"National Institute of Mental Health (NIMH)",{"id":75,"slug":76,"hasResults":12,"nctId":77,"briefTitle":78,"officialTitle":79,"acronym":4,"eligibilityCriteria":80,"healthyVolunteers":49,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":81,"targetDuration":4,"studyType":83,"phases":84,"briefSummary":86,"conditions":87,"keywords":91,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":97,"lastUpdatePostDateStruct":98,"startDateStruct":99,"completionDateStruct":101,"leadSponsor":103,"locationsCount":4},"100651864","online-sleep-education-for-college-students-sleep-health-and-executive-functioning-100651864","NCT07765849","Online Sleep Education for College Student's Sleep Health and Executive Functioning","The Role of Sleep Education in Improving Sleep Quality, Executive Functioning, and Sleep Health Literacy","Inclusion Criteria:\n\n* Be at least 18 years old\n* Be currently enrolled as an undergraduate student in a U.S. college or university\n* Have English language proficiency\n* Have internet access\n* Have an electronic device to complete an online survey\n\nExclusion Criteria:\n\n* Having a diagnosed sleep-wake disorder\n* Having a history of treatment for sleep difficulties",{"count":82,"type":21},300,"INTERVENTIONAL",[85],"NA","The goal of this clinical trial is to determine if asynchronous psychoeducational sleep intervention works to improve college students' levels of self-reported sleep health literacy, sleep quality, and executive functioning.\n\nThe main questions it aims to answer are:\n\nCan an educational sleep intervention improve college students' sleep health literacy and sleep quality? Does improved sleep health literacy impact sleep quality? Does improved sleep improve executive functioning in a college student sample?\n\nThe hypotheses of the present study include the following:\n\n* College students with poor sleep quality will have lower executive functioning\n* College students who participate in a brief educational sleep intervention will have more improvements in sleep health literacy compared to college students who do not\n* College students who participate in a brief educational sleep intervention will have more improvements in sleep quality compared to college students who do not\n* College students who participate in a brief educational sleep intervention will have more improvements in executive functioning compared to college students who do not.\n\nResearchers will compare the intervention group to a wait-list control group to see if college students who watch the psychoeducational sleep intervention have more improvements in sleep quality, sleep health literacy, and executive functioning than those who do not.\n\nParticipants will:\n\n* Complete a pre-intervention survey\n* Respond to a post-intervention survey six weeks after the pre-intervention survey\n* Be randomly assigned to watch a 30-to 45-minute psychoeducational sleep lecture video either during the pre-intervention survey or after the post-intervention survey",[25,88,89,90],"Executive Functioning","Sleep Hygiene","Health Literacy",[92,93,94,95,96],"sleep health literacy","sleep","executive functioning","sleep hygiene","college students","2026-08-10",{"date":67,"type":33},{"date":100,"type":21},"2026-09",{"date":102,"type":21},"2027-05",{"name":104,"class":105},"Northern Arizona University","OTHER",{"id":107,"slug":108,"hasResults":12,"nctId":109,"briefTitle":110,"officialTitle":111,"acronym":112,"eligibilityCriteria":113,"healthyVolunteers":49,"sex":16,"minAge":17,"maxAge":114,"enrollmentInfo":115,"targetDuration":4,"studyType":83,"phases":117,"briefSummary":118,"conditions":119,"keywords":122,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":126,"lastUpdatePostDateStruct":127,"startDateStruct":128,"completionDateStruct":130,"leadSponsor":132,"locationsCount":41},"100651115","relationships-among-pupil-responses-to-light-circadian-rhythms-and-sleep-100651115","NCT07753889","Relationships Among Pupil Responses to Light, Circadian Rhythms, and Sleep","Documenting Relationships Among Pupil Responses to Light, Circadian Rhythms, and Sleep in Healthy People and Those With Disorders or Disease","SCOPE","Inclusion Criteria:\n\n* 18-85 years old.\n* stable medically\n* ability to speak, understand and read English at a high school level\n\nExclusion Criteria:\n\n* any history of eye trauma or surgery besides correctable vision abnormalities (e.g., with glasses); any abnormalities on clinical eye exam (e.g., neuritis, Neuromyelitis optica, untreated glaucoma) such that the ophthalmologist recommends the participant not be studied;\n* prescription or non-prescription drugs affecting the pupil (e.g., affecting autonomic function), sleep, melatonin (e.g., lithium, alpha- and beta-adrenergic antagonists), and\u002For circadian rhythms (e.g., beta blockers, non-steroidal anti-inflammatory drugs, tricyclics\\\\\n* shift- or night-work in past three months;\n* crossing more than 2 time zones in past three months;\n* pregnant or less than 6 months post-partum or breastfeeding.","85 Years",{"count":116,"type":21},100,[85],"The investigators are studying relationships among eye pathology, pupil responses to light, sleep, circadian rhythms, and hormones in healthy individuals and those with various medical disorders or illnesses.\n\nAll participants will:\n\n* Answer questionnaires about their health\n* Receive an eye exam,\n* For one week at home, participants will track their sleep and wake using actigraphy (wrist worn wearable) and an online sleep diary.\n* Complete a pupillometry session (measuring pupil size in response to different lighting) at MGH\n\nParticipants may also choose to participate in the following additional procedures in any order:\n\n* Within one week of their pupillometry session, an at-home saliva collection under dim light. Saliva melatonin can be analyzed to determine Dim-Light-Melatonin-Onset (DLMO), a marker of circadian timing.\n* If participants participate in one night saliva collection, a second night of at-home saliva collection with a bright light exposure to calculate melatonin suppression in response to light.",[120,121,25],"Circadian Rhythm","Pupillometry",[123,124,125,25],"Pupil (eye)","Light","Circadian Rhythms","2026-08-06",{"date":97,"type":33},{"date":129,"type":21},"2026-09-01",{"date":131,"type":21},"2035-12",{"name":133,"class":105},"Elizabeth B Klerman MD PhD",{"id":135,"slug":136,"hasResults":12,"nctId":137,"briefTitle":138,"officialTitle":138,"acronym":4,"eligibilityCriteria":139,"healthyVolunteers":49,"sex":16,"minAge":140,"maxAge":141,"enrollmentInfo":142,"targetDuration":4,"studyType":83,"phases":144,"briefSummary":145,"conditions":146,"keywords":4,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":126,"lastUpdatePostDateStruct":147,"startDateStruct":149,"completionDateStruct":151,"leadSponsor":153,"locationsCount":156},"100611668","night-owl-sleep-study-the-effect-of-sleep-on-fecal-microbiota-100611668","NCT07243574","Night Owl Sleep Study: The Effect of Sleep on Fecal Microbiota","Inclusion Criteria:\n\n1. Men between 20 - 50 years of age and pre-menopausal women between 20 - 45 years of age (inclusive).\n2. Consistent schedule during daytime hours.\n3. BMI 18.5 - 35 kg\u002Fm2 (inclusive).\n4. Good physical and mental health as established by self-reported medical history.\n5. Willingness to maintain and record their general habits, eating, and activity\u002Fexercise pattern for the study period.\n6. Willingness to maintain and record the same time in bed they have during the workdays throughout the habitual workday sleep period.\n7. Able to alter sleeping time during the study intervention period as instructed.\n8. Willingness to maintain typical sleep hygiene patterns (e.g. sleep location, temperature, environment).\n9. Willingness to maintain their current pattern of alcohol consumption for the duration of the study.\n10. Willing and able to participate fully in all aspects of the study and complete all study procedures, including providing signed informed consent.\n11. Completes all study procedures during the 14-day screening period to be eligible for the cohort specific criteria based on the sleep data collected during the screening period.\n12. Has regular bowel habits with bowel movements on at least 5 days a week.\n13. Pittsburgh Sleep Quality Index (PSQI) score ≤10. Note: If PSQI score is between 8 and 10, PI discretion needed to confirm eligibility based on self-report screening diaries and health \\& lifestyle questionnaire.\n\nCohort specific inclusion criteria:\n\nCohort 1 (Insufficient Sleep)\n\nParticipants must meet all general inclusion criteria PLUS:\n\n1. Sleep, on average, 5-7 hours per night on workdays, verified via participant self report during the screening period. Note: Oura ring data from the run-in period will be reviewed to confirm cohort based on PI\u002FSponsor discretion.\n2. Average KSS Score of 6-10 on workdays during the screening period. Note: Use standard rounding rules for averages with decimal places.\n\nCohort 2 (Sufficient Sleep)\n\nParticipants must meet all general inclusion criteria PLUS:\n\n1. Sleep, on average, 7-9 hours per night on workdays, verified via participant self-report during the screening period. Note: Oura ring data from the run-in period will be reviewed to confirm cohort based on PI\u002FSponsor discretion.\n2. Average KSS Score of 1-5 on workdays during screening period. Note: Use standard rounding rules for averages with decimal places.\n\nExclusion:\n\n1. Any current diagnosed or self-reported sleep disorder, including but not limited to sleep apnea, habitual snoring (defined as loud, persistent snoring 3 or more nights per week), insomnia, narcolepsy, and parasomnias.\n2. Any current diagnosed or self-reported gastrointestinal disorder, including Crohn's disease, ulcerative colitis, celiac disease, IBS, or functional bowel disorder or chronic heart burn.\n3. Regularly wakes up during the night 5 or more times per night for a cumulative amount of 30 minutes as observed via self-report during the screening period, per Principal Investigator (PI) discretion.\n4. Currently taking medications (including over-the-counter medications) or dietary supplements that, in the investigator's opinion, may affect the participants' microbiome or sleep.\n5. Have taken in the last 3 months medications (including over-the-counter medications) or dietary supplements that, in the investigator's opinion, may affect the participants' microbiome or sleep.\n6. Neurodegenerative diseases (including multiple sclerosis, Parkinson's disease, Alzheimer's disease, dementia).\n7. Recent history (current use or within the past 1 month) of smoking, vaping or other use of nicotine-containing products.\n8. Recent history (past year) of alcohol abuse or dependence. Defined as regularly drinking more than 12 drinks for females and more than 20 drinks for males per week and based on PI discretion.\n9. Drug abuse or dependence, including consistent recreational substance use such as marijuana.\n10. Binge drinking behavior, defined as 4 or more alcoholic drinks for women or 5 or more alcoholic drinks for men in one sitting on 2 or more occasions, within the past 1 month with final decision per PI discretion.\n11. Diagnosed neuropsychiatric disorders or symptoms possibly affecting sleep (generalized anxiety disorder (GAD), major depressive disorder (MDD), bipolar disorder, schizophrenia)\n12. Any use of systemic antibiotics in the past 3 months. Topical or targeted antibiotic use (eye drop, ear drop) are allowed.\n13. Any use of probiotic supplements in the past 2 weeks.\n14. Any use of proton pump inhibitors (PPIs) in the past 2 weeks.\n15. Pregnant or breastfeeding or planning to become pregnant.\n16. Personal life situation causing stress or challenges in sleep (eg. caretaker required to wake up during sleep, major change in personal life). Note: Life situations causing stress or challenges in sleep that are considered short-term, per PI discretion, may be considered for re-screening 4 weeks after the life situation has resolved, meaning it is no longer causing stress or challenges in sleep.\n17. Planned overnight or cross time zone travel during the study.\n18. Females experiencing perimenopausal or menopausal symptoms, or those who have been diagnosed as perimenopausal or menopausal by a physician.\n19. Any diagnosed condition or undiagnosed symptom which disrupts sleep, including, but not limited to, hyperthyroidism, night sweats, restless legs, or poorly controlled allergic rhinitis.\n20. Extreme chronotypes for Cohort 2 (Sufficient Sleep); those that regularly go to sleep prior to 08:00 pm or after 2:30 am on 3 or more nights a week.\n21. Extreme chronotypes for Cohort 1 (Insufficient Sleep); those that regularly go to sleep prior to 08:00 pm on 3 or more nights a week.\n22. Varying work schedule and\u002For shift workers who work overnight shifts (e.g. 3rd shift, working late night to early morning hours)\n23. Any other personal or medical condition that the investigator believes may bias or confound the results.","20 Years","40 Years",{"count":143,"type":21},174,[85],"The goal of this clinical trial is to assess differences in the fecal microbiota and metabolome associated with insufficient and sufficient sleep, and to evaluate the response and recovery of the microbiota to changes in participant sleep profiles.\n\nResearchers will compare the effect of sleep intervention on both insufficient and sufficient sleepers to identify differences in fecal microbiota structure and function between cohorts during habitual sleep and during the sleep alteration intervention period..\n\nParticipants will be assigned to one of two cohorts based on their current sleep habits. Cohort 1 are participants who have insufficient sleep at baseline; this cohort will be assigned to spend 1.5 hours more in bed per night. Cohort 2 are participants who have sufficient sleep at baseline; this cohort will be assigned to spend 1.5 hours less in bed per night. The sleep intervention lasts for 14 days.",[25],{"date":148,"type":33},"2026-08-07",{"date":150,"type":33},"2025-09-17",{"date":152,"type":21},"2027-02",{"name":154,"class":155},"Danisco","INDUSTRY",3,{"id":158,"slug":159,"hasResults":12,"nctId":160,"briefTitle":161,"officialTitle":162,"acronym":4,"eligibilityCriteria":163,"healthyVolunteers":49,"sex":16,"minAge":17,"maxAge":164,"enrollmentInfo":165,"targetDuration":4,"studyType":83,"phases":166,"briefSummary":167,"conditions":168,"keywords":176,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":178,"lastUpdatePostDateStruct":179,"startDateStruct":181,"completionDateStruct":183,"leadSponsor":185,"locationsCount":41},"100529981","effect-of-sleep-extension-on-ceramides-in-people-with-overweight-and-obesity-100529981","NCT06180837","Effect of Sleep Extension on Ceramides in People With Overweight and Obesity","Biomarkers of Habitual Short Sleep and Related Cardiometabolic Risk","Inclusion Criteria:\n\n1. Age: 18-45 years old; equal numbers of men and women\n2. Body mass index (BMI): 27.5-34.9 kg\u002Fm2\n3. Sleep Habits: habitual self-reported average total sleep time (TST) \\\u003C6.5 hours per night for prior 6 months\n\nExclusion Criteria:\n\n1. Clinically diagnosed sleep disorder or major psychiatric illness\n2. Evidence of significant organ dysfunction or disease (e.g., heart disease, kidney disease)\n3. Clinically diagnosed diabetes or fasting plasma glucose ≥126 mg\u002FdL or HbA1c ≥6.5%\n4. Use of prescription drugs or substances known to influence sleep or glucose metabolism, or anticoagulant medications.\n5. Cancer that has been in remission less than 5 years\n6. Pregnant\u002Fnursing, experiencing menopause or post-menopausal\n7. Shift-work: current or history of within last year\n8. Weight change: \\>10% of body weight over prior six months\n9. Current enrollment in weight loss or physical activity program like the Diabetes Prevention Program\n10. Currently smoking\n11. Alcohol intake\\>14 drinks per week or \\>3 drinks per day","45 Years",{"count":20,"type":21},[85],"The overall goal is to determine how a sleep extension intervention (increasing time in bed) in individuals who maintain less than 6.5 hours sleep per night affects their plasma ceramides and insulin sensitivity. Participants will undergo a randomized controlled trial, with sleep extension (intervention) and healthy lifestyle (control) groups. The sleep extension is designed to increase participant's time in bed by 2 hours per night. Alternatively, the control group will receive basic health information (e.g., physical activity, goal setting, and nutrition when eating out).",[169,170,171,172,89,173,25,174,175],"Lifestyle Factors","Overweight and Obesity","Insulin Sensitivity","Eating Habit","Type 2 Diabetes","Sleep Deprivation","Insufficient Sleep Syndrome",[93,177],"insulin sensitivity","2026-08-03",{"date":180,"type":33},"2026-08-05",{"date":182,"type":33},"2024-02-12",{"date":184,"type":21},"2028-05",{"name":186,"class":105},"University of Utah",{"id":188,"slug":189,"hasResults":12,"nctId":190,"briefTitle":191,"officialTitle":192,"acronym":193,"eligibilityCriteria":194,"healthyVolunteers":49,"sex":16,"minAge":17,"maxAge":164,"enrollmentInfo":195,"targetDuration":4,"studyType":83,"phases":197,"briefSummary":198,"conditions":199,"keywords":4,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":178,"lastUpdatePostDateStruct":202,"startDateStruct":203,"completionDateStruct":205,"leadSponsor":207,"locationsCount":41},"100511760","circadian-intervention-to-improve-cardiometabolic-health-100511760","NCT05943626","Circadian Intervention to Improve Cardiometabolic Health","Timing of Circadian Synchronizers: The TOCS Study","TOCS","Inclusion Criteria:\n\n1. Age: 18-45 years old; equal numbers of men and women\n2. Body mass index (BMI): 25.0-34.9 kg\u002Fm2,\n3. Sleep Habits: habitual self-reported average total sleep time (TST) \\\u003C6.5 hours per night for prior 6 months\n\nExclusion Criteria:\n\n1. Clinically diagnosed sleep disorder or major psychiatric illness\n2. Evidence of significant organ dysfunction or disease (e.g., diagnosed diabetes, cardiovascular disease, or kidney disease)\n3. Use of prescription drugs or substances known to influence sleep or glucose metabolism\n4. Shift-work: current or history of within last year\n5. Weight change: \\>10% of body weight over prior six months\n6. Experiencing menopause or post-menopausal\n7. Current enrollment in weight loss or physical activity program like the Diabetes Prevention Program\n8. Currently pregnant or planning to become pregnant, or currently lactating.\n9. Currently smoking\n10. Alcohol intake \\>3 drinks per day or \\>14 drinks per week",{"count":196,"type":21},20,[85],"The overall goal is to examine the efficacy of a circadian intervention in people with overweight and obesity and habitual short sleep duration (HSSD). Participants will undergo a randomized controlled trial, with circadian intervention and control (healthy lifestyle) groups. The circadian intervention is designed to reduce nighttime light exposure and after-dinner snack food intake. Alternatively, the control group will receive basic health information (e.g., physical activity, goal setting, and nutrition when eating out).",[200,173,25,201,169,170,171,172,89],"Cardiometabolic Syndrome","Time Restricted Feeding",{"date":180,"type":33},{"date":204,"type":33},"2023-06-13",{"date":206,"type":21},"2027-06",{"name":186,"class":105},{"id":209,"slug":210,"hasResults":12,"nctId":211,"briefTitle":212,"officialTitle":213,"acronym":4,"eligibilityCriteria":214,"healthyVolunteers":49,"sex":215,"minAge":216,"maxAge":217,"enrollmentInfo":218,"targetDuration":4,"studyType":83,"phases":220,"briefSummary":221,"conditions":222,"keywords":234,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":239,"lastUpdatePostDateStruct":240,"startDateStruct":241,"completionDateStruct":243,"leadSponsor":245,"locationsCount":41},"100649918","dietary-supplements-and-middle-aged-women-collagen--omega-100649918","NCT07740967","Dietary Supplements and Middle Aged Women (Collagen & Omega)","The Effects of Dietary Supplements on Health and Wellbeing in Middle Aged Women","Inclusion Criteria:\n\n* Female\n* Age 35 - 65 years old\n* Healthy, free from known disease\n* Non-smoker\n* BMI of 18 - 30 kg\u002Fm2 of\n* Classified as either recreationally physically active (meet the WHO guidelines for physical activity of completing at least 150-300 min moderate-intensity activity or 75-150 min of vigorous-intensity activity a week, plus muscle-strengthening activities 2 or more days a week) OR classified as sedentary (do not meet minimum activity guidelines but do occasional and\u002For incidental physical activity (e.g., walking to work, household activities))\n\nExclusion Criteria:\n\n* Currently have a musculoskeletal injury or diagnosed condition (e.g., cardiovascular disease, osteoarthritis, diabetes, cancer, metabolic syndrome, uncontrolled hypertension, gastrointestinal disease, blood clotting disorder)\n* Regularly taking prescription medication initiated in the last 3 months or unstable\n* Have initiated hormone replacement therapy within the last 3 months and\u002For currently unstable\n* BMI not between 18-30 kg\u002Fm2\n* Allergy to ingredients in supplements or standardized breakfasts\n* Pregnant or breastfeeding, or any other contraindications to consuming study supplements\n* Lost more than 10% of body mass in past 6 months or plan on trying to lose body mass during trial period\n* Currently consuming the supplements being investigated and unwilling to stop taking them\n* Any known cognitive or visual impairments limiting ability to perform cognitive tests\n* Unwilling to maintain current diet and physical activity levels or exercise and activity levels above recreationally active (e.g., athlete)","FEMALE","35 Years","65 Years",{"count":219,"type":21},34,[85],"This study will examine the effects of combining different types of dietary supplements on various aspects of health and wellbeing in middle aged women. The main outcomes of the trial will be aspects of health and wellbeing that middle aged women report as increasingly problematic, such as joint pain, fatigue, sleep, and changes in body composition, strength, and inflammation. Participants will consume the supplement(s) or placebo for 8 weeks, and outcome measures will be assessed before and after supplementation.",[223,224,225,226,25,227,228,229,230,231,232,233],"Cognition","Inflammation Biomarkers","Bone Metabolism Biomarkers","Fatigue Symptom","Body Composition Changes","Joint Pain","Quality of Life","Gastrointestinal Comfort","Blood Pressure and Augmentation Index","Muscle Strength","Fatty Acid Blood Profile",[235,236,237,238],"Collagen peptides","Middle aged women","Joint pain","Dietary supplements","2026-07-31",{"date":178,"type":33},{"date":242,"type":33},"2026-05-01",{"date":244,"type":21},"2028-08-01",{"name":246,"class":105},"Loughborough University",{"id":248,"slug":249,"hasResults":12,"nctId":250,"briefTitle":251,"officialTitle":251,"acronym":252,"eligibilityCriteria":253,"healthyVolunteers":49,"sex":16,"minAge":254,"maxAge":217,"enrollmentInfo":255,"targetDuration":4,"studyType":83,"phases":257,"briefSummary":258,"conditions":259,"keywords":261,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":239,"lastUpdatePostDateStruct":265,"startDateStruct":267,"completionDateStruct":269,"leadSponsor":271,"locationsCount":41},"100424225","sleep-duration-and-cardiovascular-health-100424225","NCT04804124","Sleep Duration and Cardiovascular Health","Goldilocks","Inclusion Criteria:\n\n* Men and women ages 25-65y\n* Lean and overweight (BMI 18.5-40 kg\u002Fm2)\n* No acute, chronic, or debilitating medical conditions\n* No prescription\u002Fnon-prescription medications or drugs of abuse\n* Current non-smoker (tobacco and marijuana)\n* Persons who fit all the above criteria and are suitable based on a medical history and health habits questionnaire, and additional sleep and health profiling questionnaires may be eligible to participate.\n\nExclusion Criteria:\n\n* Persons with any acute, chronic, or debilitating medical condition except pre-hypertension will be excluded.\n* Persons with any symptoms of acute or active illness (e.g. fever, leukocytosis) will be excluded.\n* Persons with a history of severe psychiatric illness or psychiatric disorders will be excluded.\n* Persons with a history of regular night\u002For rotating shift work in the past year, or who have traveled more than three time zones during the one month prior to the study will be excluded.\n* Pregnant women, decisionally impaired adults, and prisoners will be excluded.","25 Years",{"count":256,"type":21},24,[85],"This is a cross-sectional study with an optional intervention that will examine how extreme sleep durations relate to cardiovascular health, physical activity, and sleep quality by studying three groups of participants: short sleepers (≤ 6 hrs), long sleepers (≥ 9 hrs), and average duration sleepers (7-8 hrs). The optional intervention asks participants to maintain an 8-hour per night regular sleep schedule for one week.",[25,260],"Cardiovascular Risk Factor",[262,263,264],"cardiovascular","sleep duration","vascular endothelial function",{"date":266,"type":33},"2026-08-04",{"date":268,"type":33},"2021-06-09",{"date":270,"type":21},"2027-09-15",{"name":272,"class":105},"Oregon Health and Science University",{"id":274,"slug":275,"hasResults":12,"nctId":276,"briefTitle":277,"officialTitle":277,"acronym":4,"eligibilityCriteria":278,"healthyVolunteers":49,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":279,"targetDuration":4,"studyType":83,"phases":281,"briefSummary":282,"conditions":283,"keywords":4,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":239,"lastUpdatePostDateStruct":284,"startDateStruct":285,"completionDateStruct":287,"leadSponsor":289,"locationsCount":41},"100253117","the-effects-of-sleep-on-human-microbiota-implications-for-health-and-disease-100253117","NCT02573753","The Effects of Sleep on Human Microbiota: Implications for Health and Disease","Inclusion Criteria:\n\n* Only subjects who are eligible for ongoing IRB-approved studies will be deemed eligible for this protocol.\n\nExclusion Criteria:\n\n* Pregnant or breast-feeding women\n* Subjects who are ineligible for ongoing IRB-approved studies will not be included in this protocol",{"count":280,"type":21},5000,[85],"The aggregate of microorganisms inhabiting the human body can be regarded as a dynamic reflector of both healthy and disease states, altering in response to changes in the environment. This may precede clinically detectable disease; and thereby, could be used to predict disease onset and additionally monitor response to treatment and predict prognosis. The primary hypothesis of this pilot study is that the human microbial communities are influenced by sleep and altered in humans with abnormal sleep patterns, and they may ultimately relate to disease risk.",[25],{"date":266,"type":33},{"date":286,"type":4},"2015-10",{"date":288,"type":21},"2031-12",{"name":290,"class":105},"Mayo Clinic",{"id":292,"slug":293,"hasResults":12,"nctId":294,"briefTitle":295,"officialTitle":296,"acronym":4,"eligibilityCriteria":297,"healthyVolunteers":12,"sex":16,"minAge":17,"maxAge":217,"enrollmentInfo":298,"targetDuration":4,"studyType":83,"phases":300,"briefSummary":302,"conditions":303,"keywords":305,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":310,"lastUpdatePostDateStruct":311,"startDateStruct":313,"completionDateStruct":315,"leadSponsor":317,"locationsCount":41},"100635404","phase-4-comparing-acupuncture-with-medication-to-reduce-depression-anxiety-and-comorbid-sleep-disorders-in-china-100635404","NCT07552246","Comparing Acupuncture With Medication to Reduce Depression, Anxiety and Comorbid Sleep Disorders in China","Comparing Acupuncture With Medication to Reduce Depression, Anxiety and Comorbid Sleep Disorders in China: A Preference-based Trial Comparing Clinical Efficacy, Cost-effectiveness and Environmental Footprint","Inclusion Criteria:\n\n1. Chinese nationals 18-65 years old\n2. At least one of the screening scores below suggestive of depression\u002Fanxiety tendencies:\n\n   1. Depressive state: Depression Self-Rating Scale (SDS) raw score ≥43; standard score ≥53 (27)\n   2. Anxiety state: Anxiety Self-Rating Scale (SAS) raw score ≥40; standard score ≥50 (28) Note: (standard score = raw score X 1.25)\n\nExclusion Criteria:\n\n1. Patients with severe comorbid physical illnesses that prevent them from completing the full course of treatment;\n2. Patients with a risk of suicide;\n3. Patients with a history of head trauma, loss of consciousness, or severe mental disorders;\n4. Patients with drugs or alcohol abuse;\n5. Patients who have received physical treatment methods within the past 3 months;\n6. Patients who have received antidepressant or antipsychotic medication treatment within the past 3 months;\n7. Patients with severe skin lesions or skin diseases.",{"count":299,"type":21},180,[301],"PHASE4","The main objective of this study is to compare medication (usual care; active comparator) with acupuncture (as experimental intervention) to identify the most (cost)effective and environmentally sustainable intervention to reduce depression, anxiety and comorbid sleep disorders in adults (18-65) in China.",[304,25],"Anxiety Depression",[306,307,308,309,93],"Depression","Acupuncture","Antidepressants","anxiety","2026-07-28",{"date":312,"type":33},"2026-07-29",{"date":314,"type":33},"2026-04-01",{"date":316,"type":21},"2027-12-31",{"name":318,"class":105},"Duke Kunshan University",{"id":320,"slug":321,"hasResults":12,"nctId":322,"briefTitle":323,"officialTitle":324,"acronym":325,"eligibilityCriteria":326,"healthyVolunteers":49,"sex":327,"minAge":17,"maxAge":141,"enrollmentInfo":328,"targetDuration":4,"studyType":83,"phases":329,"briefSummary":332,"conditions":333,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":336,"lastUpdatePostDateStruct":337,"startDateStruct":339,"completionDateStruct":341,"leadSponsor":343,"locationsCount":41},"100635460","phase-2-cbd-supplementation-in-brazilian-jiu-jitsu-athletes-100635460","NCT07552974","CBD Supplementation in Brazilian Jiu-Jitsu Athletes","Evaluation of the Effects of Isolated Cannabidiol (CBD) on Inflammation, Pain, Sleep and Quality of Life in Brazilian Jiu-Jitsu Athletes: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial","CBD-BJJ-RCT","Inclusion Criteria:\n\n* Age between 18 and 40 years;\n* Minimum 2 years of BJJ practice;\n* Training at least 3 times per week;\n* Free from injuries that prevent training or competition;\n* No current or recent cannabis use;\n* Signed Informed Consent Form (ICF).\n\nExclusion Criteria:\n\n* History of hepatic, renal, or cardiovascular diseases;\n* Use of medications that may interact with CBD (e.g., anticoagulants);\n* Allergy or known hypersensitivity to cannabinoids;\n* Pregnancy or planning to become pregnant;\n* Participation in another clinical study within the last 30 days.","MALE",{"count":116,"type":21},[330,331],"PHASE2","PHASE3","Brazilian Jiu-Jitsu (BJJ) is a high-intensity martial art that imposes significant physical and physiological demands on practitioners, including rigorous training and frequent competitions, which can result in chronic inflammation, delayed-onset muscle soreness (DOMS), sleep disturbances, and reduced quality of life. Effective recovery strategies are essential to optimize athletic performance and longevity in the sport.\n\nCannabidiol (CBD), a non-psychotomimetic phytocannabinoid derived from Cannabis sativa, has emerged as a promising therapeutic agent due to its anti-inflammatory, analgesic, anxiolytic, and neuroprotective properties.\n\nPreclinical studies indicate that CBD modulates inflammatory pathways, such as inhibition of NF-κB and NLRP3, thereby reducing pro-inflammatory cytokines such as IL-6, TNF-α, IL-8, and IL-1β, while increasing the anti-inflammatory cytokine IL-10.\n\nIn clinical contexts, CBD has shown potential to attenuate DOMS and improve sleep without the adverse effects associated with non-steroidal anti-inflammatory drugs (NSAIDs). However, evidence in BJJ athletes remains limited, with gaps in the translation of preclinical findings to healthy athletic populations.\n\nThe prevalence of injuries in combat sports can reach 28%, with contusions and sprains being common and further exacerbating inflammation and pain. Although approximately 23.4% of athletes report cannabis use, there is a lack of randomized controlled trials (RCTs) specifically for BJJ evaluating isolated CBD at standardized doses.\n\nFurthermore, concerns regarding hepatotoxicity, monitored through enzymes such as AST and ALT, require rigorous safety evaluation.\n\nThis protocol describes an RCT to investigate the effects of 200 mg\u002Fday of isolated CBD for 12 weeks in BJJ athletes, focusing on sensitive inflammatory markers (IL-6 as the primary pro-inflammatory marker and IL-10 as the anti-inflammatory marker), pain, sleep, and quality of life.\n\nThe study aims to address gaps identified in systematic reviews and provide an evidence-based foundation for future recommendations.",[334,335,25,229],"Pro and Anti Inflamatory Cytokines","Pain","2026-07-24",{"date":338,"type":33},"2026-07-27",{"date":340,"type":21},"2027-01-01",{"date":342,"type":21},"2027-07-31",{"name":344,"class":105},"Associação Pan-Americana Multidisciplinar de Endocanabinologia",{"id":346,"slug":347,"hasResults":12,"nctId":348,"briefTitle":349,"officialTitle":349,"acronym":4,"eligibilityCriteria":350,"healthyVolunteers":49,"sex":16,"minAge":17,"maxAge":164,"enrollmentInfo":351,"targetDuration":4,"studyType":83,"phases":353,"briefSummary":354,"conditions":355,"keywords":357,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":336,"lastUpdatePostDateStruct":359,"startDateStruct":360,"completionDateStruct":362,"leadSponsor":364,"locationsCount":41},"100630572","impact-of-sleep-restriction-on-blood-pressure-reactivity-100630572","NCT07489417","Impact of Sleep Restriction on Blood Pressure Reactivity","Inclusion Criteria:\n\n* Healthy adult men and women\n* 18-45 years of age\n* BMI \\\u003C 25 kg\u002Fm² (normal weight group) or ≥ 30 kg\u002Fm² (obesity group)\n* Non-pregnant, non-breastfeeding, and non-nicotine users\n* Self-reported history of normal sleep duration (7-9 hours\u002Fnight) and bedtime prior to midnight\n* Premenopausal\n\nExclusion Criteria:\n\n* No acute or chronic conditions\n* Taking no medications known to affect sleep, autonomic, metabolic, or cardiovascular function\n* Self-reported history of irregular sleep\n* Self-reported history of hepatic, renal, pulmonary, cardiovascular, or neurological disease, stroke or neurovascular disease, bleeding\u002Fclotting disorders, sleep apnea or other sleep disorders, diabetes, history of alcoholism or substance abuse, major cardiovascular event or surgical procedure within the past three months, or hypertension",{"count":352,"type":21},45,[85],"The purpose of the research study is to examine the effects of shortened sleep on blood pressure.",[25,356],"Blood Pressure",[25,358],"Blood pressure",{"date":310,"type":33},{"date":361,"type":33},"2026-03-04",{"date":363,"type":21},"2027-08",{"name":365,"class":105},"University of Missouri-Columbia",{"id":367,"slug":368,"hasResults":12,"nctId":369,"briefTitle":370,"officialTitle":371,"acronym":4,"eligibilityCriteria":372,"healthyVolunteers":12,"sex":16,"minAge":17,"maxAge":217,"enrollmentInfo":373,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":375,"conditions":376,"keywords":383,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":336,"lastUpdatePostDateStruct":384,"startDateStruct":385,"completionDateStruct":387,"leadSponsor":389,"locationsCount":41},"100624560","emotional-eating-sleep-quality-mental-state-and-metabolic-syndrome-100624560","NCT07411222","Emotional Eating, Sleep Quality, Mental State and Metabolic Syndrome","The Mediating Role of Emotional Eating and Sleep Quality in the Relationship Between Mental State and Metabolic Syndrome in Individuals With Schizophrenia and Bipolar Disorder","Inclusion Criteria:\n\n* Being registered with the Bolu İzzet Baysal Mental Health and Diseases Hospital Community Mental Health Center,\n* Having a severe chronic psychiatric illness (Schizophrenia Spectrum and Other Psychotic Disorders and Bipolar Disorder) followed by the Bolu İzzet Baysal Mental Health and Diseases Hospital Community Mental Health Center for at least 6 months,\n* Being in remission (Complete Remission (Pre-Remission): Symptoms remaining below threshold values for at least 2 months (8 weeks). A state of improvement lasting more than 2 months is generally referred to as \"remission\"),\n* Schizophrenia remission definition: 8 diagnostically significant symptoms were selected from the Positive and Negative Syndrome Scale.\n* Bipolar disorder remission definition: Complete remission is defined as the absence of acute attacks and the presence of minimal\u002Fvery mild symptoms.\n* Being between 18-65 years of age,\n* Being able to understand what is read and give written consent.\n\nExclusion Criteria:\n\n* Having a diagnosis of mental retardation,\n* Having other neurocognitive disorders, primarily dementia, according to DSM-V (as it can affect the ability to make decisions and give correct answers),\n* Not being able to speak or understand Turkish.",{"count":374,"type":21},78,"In predominantly medication-naïve schizophrenic patients, those exhibiting partial metabolic disorders have significantly worse sleep quality and sleep onset time; poor sleep predicted metabolic dysregulation even after controlling for confounding factors. Mental health, sleep, and eating behavior interact in ways that strongly influence the risk of obesity and MetS. Emotional eating (eating in response to emotions rather than hunger) is central to this network and appears to be closely associated with psychiatric illnesses, particularly depression, anxiety, and sleep disorders. There is a continuing need to elucidate the frequency, level, and relationship of emotional eating with other factors in individuals with SMI. Therefore, this study aims to elucidate this complex relationship, thereby shedding light on new ways to reduce metabolic risks in psychiatric patients.",[377,378,379,380,381,25,382],"Schizophrenia","Bipolar Disorder","Psychiatric Issue","Metabolic Syndrome","Emotional Eating","Mediating",[377,378,380,381,25],{"date":338,"type":33},{"date":386,"type":33},"2026-05-30",{"date":388,"type":21},"2026-12",{"name":390,"class":105},"Abant Izzet Baysal University",{"id":392,"slug":393,"hasResults":12,"nctId":394,"briefTitle":395,"officialTitle":396,"acronym":397,"eligibilityCriteria":398,"healthyVolunteers":49,"sex":16,"minAge":399,"maxAge":400,"enrollmentInfo":401,"targetDuration":4,"studyType":83,"phases":403,"briefSummary":404,"conditions":405,"keywords":410,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":421,"lastUpdatePostDateStruct":422,"startDateStruct":423,"completionDateStruct":425,"leadSponsor":427,"locationsCount":41},"100648882","advancing-precision-medicine-for-cardiovascular-disease-and-diabetes-in-asian-populations-digital-intervention-cohort-100648882","NCT07728799","Advancing Precision Medicine for Cardiovascular Disease and Diabetes in Asian Populations: Digital Intervention Cohort","Advancing Precision Medicine for Cardiovascular Disease and Diabetes in Asian Populations: Digital Intervention Cohort (COBRA+)","COBRA+","Inclusion Criteria:\n\n* are currently enrolled in the Singapore Population Health Studies - Multi-Ethnic Cohort Phase 3 (MEC3) or Second Follow-up (F2),\n* are of Chinese, Malay, or Indian ethnicity,\n* are 21 to 69 years old, and\n* can read and write English,\n* own or use a smartphone (iOS ≥ 12.4 or Android ≥ 8 with at least 5 GB of free storage, and data plan and internet access),\n* are able and willing to download and use study smartphone apps,\n* are able and willing to wear the smartwatch provided throughout the study period, and\n* can walk independently.\n\nExclusion Criteria:\n\n* have a history or current condition of stroke, heart attack, kidney failure, diabetes mellitus, thyroid disease, or cancer, or have had a vascular bypass surgery or angioplasty procedure (either stent or balloon) performed, or\n* a serious mental health condition including schizophrenia, psychotic depression, or severe dementia, or\n* are currently pregnant or planning to get pregnant during the study period, or\n* are participating or planning to participate in other lifestyle intervention studies.\n* have a known sensitivity to medical-grade adhesives or a bleeding disorder will be \\[applicable to continuous glucose monitoring component only\\]\n* with contraindications specified by the blood pressure monitoring device manufacturer \\[applicable to continuous blood pressure monitoring component only\\]\n* participated in the pilot study \\[applicable to main trial only\\].","21 Years","69 Years",{"count":402,"type":21},600,[85],"The overarching aim is to improve cardiometabolic health and promote healthy ageing by supporting adults to adopt favourable lifestyle patterns identified through our observational research. The trial will recruit n=600 to be involved in Phase I (referred to as the \"Optimisation Phase\") of a two-phase project (Phase II trial registration will be submitted separately). All participants will complete a baseline study visit where, after consent taking, will complete a baseline questionnaire, receive a smartwatch each and additional wearables if applicable, and download the study app for the receiving and testing of interventions and completion of short form surveys. Participants will be involved in the continual evaluation and optimisation of ecological momentary interventions (EMIs) in adaptive, factorial, micro-randomised trials over 12 months. Consenting participants may also be contacted to participate in interviews to be involved in the co-design of interventions, or to provide insights to the feasibility and process evaluation of the trial.",[406,407,25,408,409],"Physical Activity","Diet Quality","Cardiometabolic Health","Digital Intervention",[411,412,413,414,415,416,417,418,419,420],"smartphone","smartwatch","ecological momentary assessment","EMA","ecological momentary intervention","EMI","microrandomised trial","mHealth","digital health","intervention","2026-07-23",{"date":338,"type":33},{"date":424,"type":21},"2026-07-20",{"date":426,"type":21},"2031-06-30",{"name":428,"class":105},"National University of Singapore",{"id":430,"slug":431,"hasResults":12,"nctId":432,"briefTitle":433,"officialTitle":434,"acronym":4,"eligibilityCriteria":435,"healthyVolunteers":12,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":436,"targetDuration":4,"studyType":83,"phases":438,"briefSummary":439,"conditions":440,"keywords":442,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":443,"lastUpdatePostDateStruct":444,"startDateStruct":445,"completionDateStruct":447,"leadSponsor":449,"locationsCount":41},"100649109","personalised-sleep-and-circadian-intervention-after-stroke-100649109","NCT07731516","Personalised Sleep and Circadian Intervention After Stroke","Feasibility, Efficacy, and Patient Experience of a Personalised Transdiagnostic Intervention for Sleep and Circadian Dysfunction Following Stroke: a Mixed-method Randomised Controlled Feasibility Trial","Inclusion Criteria:\n\n1. \\>6 months from last stroke\n2. aged ≥18 years\n3. Cantonese language fluency\n4. ≥1 self-reported sleep or circadian problem(s) for 3 months: ≥30 min to get to sleep on ≥3 nights per week, waking in the middle of night ≥30 min on ≥3 nights per week, \\\u003C6-hr sleep per night or ≥9-hr sleep per 24 hour period on ≥3 nights per week, ≥1.09 hours of variability in sleep-wake schedule across one week, and\u002For bedtime after 2:00 a.m. on ≥3 nights per week\n5. adequate opportunities for sleep.\n\nExclusion Criteria:\n\n1. presence of an active and progressive physical or neurocognitive illness or substance abuse making participation infeasible\n2. past or current involvement in psychological treatment for sleep issues\n3. night shift work\n4. pregnancy or breastfeeding.",{"count":437,"type":21},40,[85],"This is a two-arm, parallel-group randomized controlled feasibility trial involving 40 community-dwelling adults with chronic stroke and ongoing sleep or circadian difficulties. Participants will be randomly assigned in a 1:1 ratio to either an individualized behavioral sleep intervention or an attention-matched health education program.\n\nBefore randomization, participants will complete questionnaires assessing sleep and related health outcomes, maintain a sleep diary, and wear a wrist-worn activity monitor for seven days. Participants will then attend six weekly, individual, face-to-face sessions lasting approximately one hour each.\n\nThe behavioral sleep intervention will provide individualized education and behavioral strategies to support sleep and daily sleep-wake functioning following stroke. The comparison program will provide education about stroke, sleep, and general health. The two programs will be matched in session frequency and duration.\n\nFollowing the six-week program, participants will repeat the questionnaires, sleep diary, and seven-day wrist-monitoring assessment. Participants will also provide feedback about their experiences with the study and program.\n\nThe trial will evaluate recruitment, retention, attendance, intervention delivery, acceptability, fidelity, and safety. Preliminary changes in sleep and sleep-wake outcomes will also be examined.",[441,25],"Stroke",[441,25,120],"2026-07-22",{"date":310,"type":33},{"date":446,"type":21},"2026-08",{"date":448,"type":21},"2028-07",{"name":450,"class":105},"The Hong Kong Polytechnic University",{"id":452,"slug":453,"hasResults":12,"nctId":454,"briefTitle":455,"officialTitle":213,"acronym":4,"eligibilityCriteria":456,"healthyVolunteers":49,"sex":215,"minAge":216,"maxAge":217,"enrollmentInfo":457,"targetDuration":4,"studyType":83,"phases":459,"briefSummary":221,"conditions":460,"keywords":462,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":465,"lastUpdatePostDateStruct":466,"startDateStruct":467,"completionDateStruct":468,"leadSponsor":470,"locationsCount":41},"100649225","dietary-supplements-and-middle-aged-women-creatine-100649225","NCT07729930","Dietary Supplements and Middle Aged Women (Creatine)","Inclusion Criteria:\n\n* Female\n* Aged 35-65 years old\n* Healthy, free from known disease\n* Non-smoker\n* BMI 18-30 kg\u002Fm2\n* Classified as recreationally active (meet the WHO guidelines for physical activity: complete at least 150-300 minutes of moderate intensity activity or 75-150 minutes of vigorous intensity activity a week, plus muscle strengthening activities 2 or more days a week) OR sedentary (do not meet the minimum activity guidelines but do occasional and\u002For incidental physical activity, e.g., walking to work, household activities).\n\nExclusion Criteria:\n\n* Currently have a musculoskeletal injury or diagnosed condition (CVD, osteoarthritis, diabetes, cancer, metabolic syndrome, uncontrolled hypertension, gastrointestinal disease, blood clotting disorder)\n* Regularly taking prescription medication initiated in the last 3 months or unstable\n* Have initiated hormone replacement therapy within the last 3 months or unstable\n* Have an allergy to ingredients in the supplements or standardised breakfast\n* Pregnant or breastfeeding, or any other contradictions to consuming the study supplements\n* Lost more than 10% of body mass in the past 6 months or plan on trying to lose body mass during trial period\n* Currently consuming the supplements being investigated and unwilling to stop\n* Any known cognitive or visual impairments limiting ability to perform cognitive tests\n* Unwilling to maintain current diet and physical activity levels and report any change in health status",{"count":458,"type":21},38,[85],[223,232,226,231,227,25,230,229,228,224,225,461],"Menopause Symptoms",[463,236,464,238],"Creatine","Cognitive function","2026-07-21",{"date":310,"type":33},{"date":242,"type":33},{"date":469,"type":21},"2028-11-01",{"name":246,"class":105},{"id":472,"slug":473,"hasResults":12,"nctId":474,"briefTitle":475,"officialTitle":475,"acronym":4,"eligibilityCriteria":476,"healthyVolunteers":49,"sex":16,"minAge":17,"maxAge":477,"enrollmentInfo":478,"targetDuration":4,"studyType":83,"phases":479,"briefSummary":480,"conditions":481,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":465,"lastUpdatePostDateStruct":482,"startDateStruct":483,"completionDateStruct":485,"leadSponsor":487,"locationsCount":4},"100648682","ganmaidazao-concentrated-beverage-sleep-assisting-trial-100648682","NCT07726719","Ganmaidazao Concentrated Beverage Sleep-Assisting Trial","Inclusion Criteria:\n\n* Aged 18 to 60 years of any gender, with a history of staying up late or mild sleep disorder, and Pittsburgh Sleep Quality Index (PSQI) score between 7 and 15 points (mild to moderate sleep impairment).\n* Regular daily schedule with bedtime from 22:00 to 24:30 and wake-up time from 6:30 to 8:30; long-term daily schedule fluctuation ≤ 2 hours, and able to maintain a fixed schedule throughout the trial.\n* No abnormal saliva secretion and capable of completing saliva sample collection independently and normally.\n* Body Mass Index (BMI) ranging from 18.5 to 28.0, without extreme emaciation or obesity.\n* Able to participate in pre-trial centralized training and operational assessments (including wearable bracelet wearing, saliva collection, and questionnaire filling), and pass the assessment before enrollment.\n* No intake of sleep aids, anti-anxiety drugs, antidepressants, central nervous system regulators, sleep-improving health foods and related products within 2 weeks prior to enrollment.\n* Free from severe organic diseases, including cardiovascular and cerebrovascular diseases, liver and kidney dysfunction, psychiatric disorders, and nervous system diseases.\n* Free from severe sleep disorder subtypes, such as obstructive sleep apnea syndrome.\n* No history of allergy to the ingredients and excipients of the test product, and voluntarily sign the informed consent form.\n\nExclusion Criteria:\n\n* Aged under 18 years or over 60 years.\n* Current smokers, or subjects with alcohol drinking habits of ≥3 times per week who have not quit alcohol within one month before the trial.\n* Long-term intake of stimulating beverages, defined as drinking strong tea, coffee or energy drinks ≥3 cups per day.\n* Experienced drastic changes in diet or daily routine within one month before enrollment, such as frequent business trips, travel, shift work, or dramatic dietary habit changes.\n* Diagnosed with severe sleep disorders or obstructive sleep apnea syndrome.\n* Participated in other human clinical trials, received professional sleep intervention therapy, or consumed products containing N-acetylneuraminic acid within one month before enrollment.\n* Pregnant or lactating females, or those planning to become pregnant within one year.\n* Long-term shift workers, regular severe night owls, or subjects with extremely unstable sleeping environments.\n* Intolerant to wearing smart wearable bracelets or unable to cooperate with trial-related examinations and sample collection.\n* Staff of the trial institution and other personnel involved in this project.\n* Scheduled to receive surgical treatment during the trial period.\n* With a history of severe food or drug allergies.\n* Diagnosed with digestive system organic lesions such as gastrointestinal ulcers and bleeding.\n* Suffering from severe physical and mental illnesses under treatment, severe cardiovascular, cerebrovascular and hematological diseases, severe liver and kidney dysfunction, pulmonary infection or malignant tumors.","60 Years",{"count":7,"type":21},[85],"A human trial with blind method and self-control design was carried out to evaluate the sleep-improving function of a food. Indicators were detected by professional instruments and self-assessed by subjects. Relevant data before and after 28 consecutive days of test sample administration were collected for comparative analysis.",[25],{"date":336,"type":33},{"date":484,"type":21},"2026-08-01",{"date":486,"type":21},"2026-10-30",{"name":488,"class":155},"Sirio Pharma Co., Ltd",{"id":490,"slug":491,"hasResults":12,"nctId":492,"briefTitle":493,"officialTitle":494,"acronym":495,"eligibilityCriteria":496,"healthyVolunteers":12,"sex":16,"minAge":497,"maxAge":498,"enrollmentInfo":499,"targetDuration":4,"studyType":83,"phases":501,"briefSummary":502,"conditions":503,"keywords":505,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":424,"lastUpdatePostDateStruct":510,"startDateStruct":511,"completionDateStruct":512,"leadSponsor":514,"locationsCount":41},"100629612","differences-in-rest-emotion-and-arousal-modulation-in-youth-100629612","NCT07476937","Differences in Rest, Emotion, and Arousal Modulation in Youth","Probing the Role of Sensory Regulation in Sleep Health and Emotion Dysregulation for Autistic Youth","DREAMY-Autism","Inclusion Criteria:\n\n1. Youth between the ages of 6 and 10 years old\n2. Caregiver-reported autism diagnosis and \\>11 on Social Communication Questionnaire\n3. Caregiver-reported bedtime resistance (\\>12 on Children's Sleep Habits Questionnaire-Autism; Sleep Initiation subscale - 3-point scale, 6 questions)\n4. Caregiver willing to participate in all bedtimes during study\n5. Stable medication use (e.g., no changes within 2 weeks)\n\nExclusion Criteria:\n\n1. Participants will be excluded if they do not understand English or are unable to travel to the lab (Pittsburgh, PA).\n2. Concurrent diagnosis of sleep apnea, narcolepsy, or major psychiatric disorder (e.g., major depression, bipolar).\n3. Unstable medication use (dose or timing).\n4. Current behavioral treatment for sleep disorder","6 Years","10 Years",{"count":500,"type":21},60,[85],"The goal of this study is to examine the relationship between sensory responsivity, bedtime arousal levels, sleep disturbances, and daytime emotion dysregulation for autistic children (ages 6-10). In a subset of children with elevated sensory responsivity, a sensory-based bedtime manipulation targeting bedtime arousal levels will be tested.",[62,504,25],"Sleep Disturbances in Children",[506,507,508,25,509],"Sleep disturbances","Emotion Dysregulation","Sensory Processing","autism",{"date":443,"type":33},{"date":424,"type":33},{"date":513,"type":21},"2030-08",{"name":515,"class":105},"University of Pittsburgh",{"id":517,"slug":518,"hasResults":12,"nctId":519,"briefTitle":520,"officialTitle":520,"acronym":521,"eligibilityCriteria":522,"healthyVolunteers":49,"sex":16,"minAge":17,"maxAge":141,"enrollmentInfo":523,"targetDuration":4,"studyType":83,"phases":524,"briefSummary":525,"conditions":526,"keywords":4,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":424,"lastUpdatePostDateStruct":528,"startDateStruct":529,"completionDateStruct":531,"leadSponsor":533,"locationsCount":41},"100624574","assessment-and-characterization-of-sleep-among-video-game-adult-players-without-video-game-use-disorder--a-feasability-study-100624574","NCT07411404","Assessment and Characterization of Sleep Among Video Game Adult Players Without Video Game Use Disorder : a Feasability Study","SLEEPLAY","Inclusion Criteria:\n\n* Women and men aged 18 to 40\n* Signed informed consent form\n* For regular gamers: playing video games at least 3 times a week in the past 2 years, with IGDT-10 (Ten-Item Internet Gaming Disorder Test) \\> 5\n* For control group: non-player or occasional player (at least once in the previous year, but less than once a month)\n\nExclusion Criteria:\n\n* Night worker\n* WIth treatment for sleep disorder or interfering with melatonin secretion (betablokers, melatonin supplements,some antidepressants)\n* Any pathology leading to circadian rythm disorder, neurological or psychiatric disorder\n* major addiction (any game or gambling disorder) except for coffee and tabacco",{"count":437,"type":21},[85],"The primary objective of the SLEEPLAY study is to assess the feasibility of a research protocol investigating the impact of video games on sleep in adults. More specifically, this study aims to identify potential barriers, facilitators of participation, and participant adherence to various measurement tools (such as actigraphy and melatonin assays) to validate the protocol for a larger future study. Additionally, it seeks to optimize the recruitment of regular adult gamers and determine the conditions that will enable better collection of objective sleep data. The relevance of this feasibility study lies in its ability to test and refine the methodology, thereby facilitating future research while minimizing costs and implementation time.",[25,527],"Video Gamers",{"date":443,"type":33},{"date":530,"type":33},"2025-12-01",{"date":532,"type":21},"2027-09",{"name":534,"class":105},"Centre Hospitalier Universitaire de Besancon",{"id":536,"slug":537,"hasResults":12,"nctId":538,"briefTitle":539,"officialTitle":540,"acronym":541,"eligibilityCriteria":542,"healthyVolunteers":12,"sex":16,"minAge":543,"maxAge":4,"enrollmentInfo":544,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":545,"conditions":546,"keywords":4,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":424,"lastUpdatePostDateStruct":549,"startDateStruct":550,"completionDateStruct":552,"leadSponsor":553,"locationsCount":41},"100402884","real-world-evidence-in-patient-reported-outcomes-for-medical-cannabis-mc-rwe-100402884","NCT04526093","Real-World Evidence in Patient-Reported Outcomes for Medical Cannabis (MC-RWE)","MC-RWE : Real World Evidence in Patient-Reported Outcomes for Medical Cannabis: A Prospective Observational Study","MC-RWE","Inclusion Criteria:\n\n* Subjects (≥19 years of age) who are MC-naïve or -experienced with a medical authorization for MC provided by a prescribing health care practitioner and who have provided informed consent\n* Primary therapeutic indications for MC use: pain, epilepsy, sleep, and\u002For anxiety\u002Fdepression.\n* Subjects agree to use verified products and refrain from using any other cannabis products, either medical or recreational, during the duration of the study\n\nExclusion Criteria:\n\n* Concomitant use of illicit drugs\n* Concomitant use of recreational cannabis","19 Years",{"count":53,"type":21},"This prospective observational study aims to describe the effectiveness of MC on pain, epilepsy, sleep and \u002For anxiety\u002Fdepression in a cohorts of patients authorized to use MC, using pre-defined, validated self assessment scales.",[335,25,547,306,548],"Anxiety","Epilepsy",{"date":443,"type":33},{"date":551,"type":33},"2020-07-15",{"date":448,"type":21},{"name":554,"class":105},"University Health Network, Toronto",{"id":556,"slug":557,"hasResults":12,"nctId":558,"briefTitle":559,"officialTitle":560,"acronym":561,"eligibilityCriteria":562,"healthyVolunteers":12,"sex":16,"minAge":563,"maxAge":17,"enrollmentInfo":564,"targetDuration":4,"studyType":83,"phases":566,"briefSummary":567,"conditions":568,"keywords":573,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":577,"lastUpdatePostDateStruct":578,"startDateStruct":579,"completionDateStruct":581,"leadSponsor":583,"locationsCount":41},"100573383","improving-sleep-decision-making-and-eating-in-adolescents-with-obesity-100573383","NCT06745570","Improving Sleep, Decision-Making, and Eating in Adolescents With Obesity","Improving Sleep as a Method for Enhancing Decision-Making and Reducing Problematic Eating Behaviors in Adolescents With Obesity","STAR","Inclusion Criteria:\n\n* Ages 14-18\n* Fluent in English\n* BMI percentile ≥ 85th percentile for sex-and-age\n* Has a parent or guardian who is willing and able to participate\n* Has at least one sleep disturbance. Eligible sleep disturbances are: a. Advanced sleep timing (sleep onset 11:00pm or later for 14-16 year-olds or 11:20pm or later for 17-18 year-olds at least 3 times per week), b. Difficulty falling asleep (taking ≥ 30 mins to get to sleep 3 or more nights per week), c. Short sleep (obtaining \\\u003C 7.5 hours of sleep per night 3 or more nights per week), and d. Sleep irregularity (having more than 2 hours of variability in sleep-wake schedule across one week\n\nExclusion Criteria:\n\n* Experience of weight loss of ≥ 5% of body weight in the past 6 months\n* Current use of insomnia medication\n* Having recently begun or changed the dosage of any medication known to affect appetite or body composition within the last 3 months\n* Currently taking weight loss medications\n* Currently taking insulin\n* Diagnosed diabetes (type 1)\n* Any condition prohibiting physical activity\n* Diagnosis of an eating disorder\n* Diagnosis of obstructive sleep apnea\n* Recent or ongoing problem with drug abuse, alcohol abuse, or addiction\n* Currently pregnant or less than 3 months postpartum\n* Anticipation of a possible pregnancy in the next year\n* Unwillingness to report possible or confirmed pregnancies promptly during the course of the trial\n* Currently participating in treatment for eating or weight concerns\n* Does not have regular access to Wi-Fi connection to participate in study interventions.","14 Years",{"count":565,"type":21},50,[85],"This study is being performed to understand the effects of a lifestyle modification and sleep intervention on weight loss outcomes in adolescence. The main question the study aims to answer is:\n\n\\- What are the initial effects of a lifestyle modification and sleep intervention, including effects on weight, eating behaviors and dietary intake, and sleep?\n\nParticipants will:\n\n* Participate in remote, group-based, weekly weight loss and sleep coaching for 16 weeks.\n* Complete study assessments at baseline (pre-intervention), mid-intervention, and post-intervention.\n* Complete daily sleep diaries for three 7-day periods at each assessment point.",[569,570,25,571,572],"Adolescent Overweight","Adolescent Obesity","Eating Behaviors","Dietary Intake",[574,575,576],"Adolescent Weight Loss","Adolescent Sleep","Adolescent Eating","2026-07-16",{"date":424,"type":33},{"date":580,"type":33},"2024-04-18",{"date":582,"type":21},"2027-01-31",{"name":584,"class":105},"Nemours Children's Clinic",{"id":586,"slug":587,"hasResults":12,"nctId":588,"briefTitle":589,"officialTitle":590,"acronym":4,"eligibilityCriteria":591,"healthyVolunteers":12,"sex":16,"minAge":17,"maxAge":217,"enrollmentInfo":592,"targetDuration":4,"studyType":83,"phases":594,"briefSummary":595,"conditions":596,"keywords":598,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":600,"lastUpdatePostDateStruct":601,"startDateStruct":603,"completionDateStruct":605,"leadSponsor":607,"locationsCount":41},"100459977","phase-2-mechanisms-of-cannabidiol-in-persons-with-ms-the-role-of-sleep-and-pain-phenotype-100459977","NCT05269628","Mechanisms of Cannabidiol in Persons With MS: the Role of Sleep and Pain Phenotype","Mechanisms of Cannabidiol (CBD) in Persons With Multiple Sclerosis (MS): the Role of Sleep and Pain Phenotype","Inclusion Criteria:\n\n1. Patients with clinically definite MS (those who are on a disease modifying therapy must be on a stable dose without evidence of liver toxicity for at least 3 months);\n2. Presence of chronic pain defined as moderate to severe pain for at least 3 months, based on a 0-10 numeric rating scale (NRS);\n3. Willingness to maintain stable analgesic regimen during study period;\n4. Recent serum aspartate transaminase, alanine transaminase, and bilirubin testing within 90 days of screening;\n\nExclusion Criteria:\n\n1. Current shift work sleep disorder, or narcolepsy diagnosed with polysomnography and multiple sleep latency test;\n2. History of MS relapse within the last 30 days prior to screening (participants will be considered eligible after the 30-day window);\n3. Pain due to cancer;\n4. Pregnancy or breastfeeding;\n5. Current cannabinoid use (participants may be reconsidered for inclusion after 30-day washout) and\u002For unwillingness to abstain from cannabinoids in any form from 30 days prior to the study of the study drugs and until the last follow up phone call at the end of the study (30 - 37 days after taking the last dose of the study drug).\n6. Unwillingness to use contraception from screening until the end of drug treatment\n7. Current suicidal ideation (SI) with intent and\u002For plan; these individuals will be assessed by a study psychologist and referred for urgent mental health treatment as indicated;\n8. Current severe depression as indicated by a PHQ-9 score of ≥ 17 that includes indicators of significant depressed mood (sum of items #1 and #2 ≥ 5).\n9. History of mania or schizophrenia diagnosis\n10. Known hypersensitivity to cannabinoids in general, or Epidiolex® or Dronabinol specifically or its excipients (e.g., sesame oil)\n11. History of the following cardiovascular conditions: recent myocardial infarction or stroke (last 6 months prior to screening), unstable angina, left ventricular hypertrophy, mitral valve prolapses, severe coronary artery disease, NYHA class III or IV congestive heart failure.\n12. History severe hepatic impairment (must have blood AST ≤ 2.0x ULN, ALT ≤ 2,0x ULN, and bilirubin ≤ 1.5x ULN within the last 90 days (AST, ALT, bilirubin testing will be required within 90 days of screening);\n13. History of seizure disorder (recurrent, unprovoked seizures not explained by a known reversible cause) or history of certain types of head injury that could cause an increased risk of seizures;\n14. History of prescription or illicit drug abuse (such as cocaine, amphetamine, methamphetamine, heroin);\n15. Current risk for alcohol misuse as indicated by a score of ≥ 8 on the Alcohol Use Disorders Identification Test (AUDIT) self-report measure.\n16. Current warfarin, valproate or clobazam use.\n17. Current use of known moderate or strong inhibitors of CYP3A4 \\[topical ketoconazole, and temporary (\\\u003C= 4 week) oral courses of clarithromycin, fluconazole and itraconazole will be allowed\\].\n18. Current use of strong inducers of CYP3A4 or CYP2C19 (does not include glucocorticoids or modafinil\u002Farmodafinil, which are permitted),\n19. Current use of moderate or strong inhibitors\u002Finducers of CYP2C9, and narrow therapeutic index drugs (e.g., cyclosporine, amphotericin B).\n20. Current use of known non-minor Sensitive CYP2C19 Substrates, with the exception of some proton pump inhibitors (e.g., esoprazole, omeprazole)), periodic self-limited courses of diazepam (e.g., for MRI sedation) and submaximal doses of some antidepressant class medications (e.g., citalopram, and escitalopram), which will be permitted by the discretion of the treating neurologist PI.\n21. Refusal to avoid grapefruit or grapefruit products during the study treatment interval.\n22. Current use of opioids (tramadol permitted).\n23. Employed as a commercial driver or employed in an occupation that involves extreme heights or use of heavy machinery.\n24. History of car crashes or near-crashes due to untreated sleepiness that has led to near-misses in the past 6 months.\n25. Cognitive dysfunction as indicated by \\>=3 errors on the six-item cognitive screener\n26. Expanded Disability Status Scale (EDSS) score \\>=8.0.\n27. Blood pressure at screening above 180 mmHg systolic and\u002For 120 mmHg diastolic, or below 90 mmHg systolic and or 60 mmHg diastolic, or history of syncope related to orthostatic hypotension;\n28. Resting heart rate at screening less than 50 bpm or greater than 100 bpm;\n29. Any other treatment or medical, neurological, sleep, or psychiatric condition that, in the opinion of the investigators, could affect participant safety or eligibility.",{"count":593,"type":21},166,[330],"The purpose of this research study is to compare the effects of cannabidiol (CBD), tetrahydrocannabinol (THC), or both, on sleep and pain in persons with multiple sclerosis (MS). Little is known about how CBD and\u002For THC may help sleep, reduce pain, or perhaps even treat pain through better sleep.",[597,25,335],"Multiple Sclerosis",[599],"Cannabidiol","2026-07-15",{"date":602,"type":33},"2026-07-17",{"date":604,"type":33},"2022-03-25",{"date":606,"type":21},"2027-08-30",{"name":608,"class":105},"Tiffany J. Braley, MD, MS",{"id":610,"slug":611,"hasResults":12,"nctId":612,"briefTitle":613,"officialTitle":614,"acronym":4,"eligibilityCriteria":615,"healthyVolunteers":12,"sex":16,"minAge":616,"maxAge":4,"enrollmentInfo":617,"targetDuration":4,"studyType":83,"phases":619,"briefSummary":620,"conditions":621,"keywords":623,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":627,"lastUpdatePostDateStruct":628,"startDateStruct":629,"completionDateStruct":631,"leadSponsor":633,"locationsCount":635},"100642077","circadian-synchronized-breast-milk-feeding-and-sleep-in-preterm-infants-a-multicenter-randomized-controlled-trial-100642077","NCT07645677","Circadian-Synchronized Breast Milk Feeding and Sleep in Preterm Infants: A Multicenter Randomized Controlled Trial","Effect of Circadian-Synchronized Breast Milk Feeding on Sleep in Preterm Infants: A Multicenter Randomized Controlled Trial","Inclusion Criteria:\n\n* Preterm infants born between 28 weeks and 36 weeks plus 6 days of gestation.\n* Infants who have reached full enteral feeding.\n* Written informed consent signed by a legal guardian.\n\nExclusion Criteria:\n\n* Need for invasive respiratory support, such as endotracheal intubation.\n* Use of sedatives or other medications that may affect the central nervous system or sleep rhythm.\n* Presence of congenital neurologic or chromosomal abnormalities.\n* Presence of congenital gastrointestinal malformations or anorectal malformations.\n* Conditions affecting digestion or absorption, such as diarrhea, intestinal obstruction, or necrotizing enterocolitis.\n* Critical illnesses such as patent ductus arteriosus, neonatal sepsis, neutropenia, or coagulation disorders.","0 Days",{"count":618,"type":21},120,[85],"This clinical trial aims to find out whether a circadian-synchronized breast milk feeding approach can help improve sleep in preterm infants in the neonatal intensive care unit (NICU).\n\nThe study mainly aims to answer the following questions:\n\nCan this feeding approach improve sleep in preterm infants? Can this feeding approach help preterm infants develop more regular sleep patterns compared with routine breast milk feeding?\n\nResearchers will compare a feeding approach that tries to match the time when breast milk was expressed with the time when the baby is fed, with routine breast milk feeding, to see whether this method can improve sleep in preterm infants.\n\nParticipants will:\n\nBe randomly assigned to 1 of 2 groups: circadian-synchronized breast milk feeding or routine breast milk feeding.\n\nReceive the assigned feeding approach for at least 2 weeks during the study. Have one 12-hour continuous sleep monitoring session at 37 weeks of corrected age.\n\nHave changes in different sleep states recorded and analyzed during the study, so that sleep patterns can be compared between the 2 groups.",[622,25],"Preterm Infant",[624,120,625,626,622,25],"Breast Milk Feeding","Chrononutrition","NICU","2026-07-14",{"date":577,"type":33},{"date":630,"type":21},"2026-07-01",{"date":632,"type":21},"2027-08-01",{"name":634,"class":105},"Shanghai Jiao Tong University School of Medicine",6,{"id":637,"slug":638,"hasResults":12,"nctId":639,"briefTitle":640,"officialTitle":640,"acronym":641,"eligibilityCriteria":642,"healthyVolunteers":49,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":643,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":645,"conditions":646,"keywords":650,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":665,"lastUpdatePostDateStruct":666,"startDateStruct":667,"completionDateStruct":668,"leadSponsor":670,"locationsCount":672},"100643789","neonatal-neurological-observation-with-video-ai-100643789","NCT07628829","Neonatal Neurological Observation With Video AI","NeoNOVA","Inclusion Criteria:\n\n* Signed and dated informed consent from at least one parent or legally authorized representative (LAR) who is at least 18 years old.\n* Parent\u002FLAR expresses willingness to comply with study procedures for the duration of the infant's hospital stay.\n* Infant of any sex (including intersex\u002Fundetermined) admitted to newborn services (including the NICU) at a participating hospital.\n\nExclusion Criteria:\n\n* Parents or LAR unable to provide informed consent or are under the age of 18.\n* Non-viable neonates",{"count":644,"type":21},200,"NeoNOVA is a multi-site, prospective, single-arm, silent observational study to determine: among (Population) infants admitted to newborn services during their inpatient hospital stay, whether (Intervention) continuous bedside non-contact high definition video running real-time AI analysis of anatomic landmarks and movement, (Comparison) compared against human-labeled video frames and standardized clinical exams, will (Outcome) accurately localize infant anatomic landmarks (primary objective; outcome median position error in pixels) and demonstrate a statistically significant association between a video-derived movement index and clinical measures of patient neurological exams (secondary objective; outcomes N-PASS and modified Sarnat exams).",[647,648,649,25],"Neonatal Encephalopathy","Hypoxic-Ischemic Encephalopathy","Sedation",[651,652,653,654,655,656,657,626,658,649,659,660,661,662,663,664],"Pose AI","Neonatal","Neonate","AI","Video AI","artificial intelligence","computer vision","Encephalopathy","neonatal monitoring","movement analysis","pose estimation","machine learning","neurological assessment","spontaneous movement","2026-07-13",{"date":600,"type":33},{"date":665,"type":33},{"date":669,"type":21},"2029-07-12",{"name":671,"class":155},"Artemis AI Labs",2]